Advanced Refractory Solid Tumors
12
2
3
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
1 terminated out of 12 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors
Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors